OsteoStrong, the global leader in osteogenic loading technology for bone health, proudly announces that a groundbreaking study on its proprietary system has been accepted for publication in The Journal of Clinical Endocrinology & Metabolism (JCEM). The study, titled Effective Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis, was conducted by leading researchers Nektaria Papadopoulou-Marketou, Anna Papageorgiou, Nikolaos Marketos, Panagiotis Tsiamyrtzis, Georgios Vavetsis, and George P. Chrousos. This milestone underscores the significant role OsteoStrong® plays in improving bone health and reducing osteoporosis-related risks in postmenopausal women.

Health Technology Insights: Eastern Michigan University Professor Leads Effort to Study Protein’s Impact

Key Findings of the Study

The study evaluated the effectiveness of OsteoStrong®’s intervention in 147 postmenopausal women diagnosed with osteoporosis. Participants were divided into two groups: one receiving the OsteoStrong® intervention and another control group without the intervention. Key results include:

  • Increased Bone Mineral Density (BMD): Statistically significant increases in BMD were observed in the lumbar spine (L1-L4), right and left femoral neck, and total femur in participants utilizing OsteoStrong®.
  • Enhanced Trabecular Bone Score (TBS): OsteoStrong® intervention improved TBS, indicating better bone microarchitecture and reduced fracture risk.
  • Synergistic Effect with Antiresorptive Therapy: The study found that OsteoStrong® enhanced the effectiveness of antiresorptive medications, further boosting bone density improvements.
  • Non-Medication Benefits: Even participants who were not on antiresorptive medications showed significant improvements in bone density.

Health Technology Insights: New Research: Rising Demand for Fertility & Family Benefits

“These findings reinforce what we have seen anecdotally for years—OsteoStrong®’s unique approach to osteogenic loading significantly improves bone health,” said Kyle Zagrodzky, CEO and Founder of OsteoStrong. “The acceptance of this research in a prestigious, peer-reviewed medical journal like JCEM is a monumental step in validating OsteoStrong® as a science-backed solution for osteoporosis management.”

Health Technology Insights: TRX Launches New Physical Therapy & Rehabilitation Tools & Education

To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com

Source – prnewswire